Morris Christopher J, Rolf Michael G, Starnes Linda, Villar Inmaculada C, Pointon Amy, Kimko Holly, Di Veroli Giovanni Y
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, United Kingdom.
Safety Sciences, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Gothenburg, Sweden.
Front Pharmacol. 2024 Oct 29;15:1402462. doi: 10.3389/fphar.2024.1402462. eCollection 2024.
Pharmaceutical companies routinely screen compounds for hemodynamics related safety risk. secondary pharmacology is initially used to prioritize compounds while studies are later used to quantify and translate risk to humans. This strategy has shown limitations but could be improved via the incorporation of molecular findings in the animal-based toxicological risk assessment. The aim of this study is to develop a mathematical model for rat and dog species that can integrate secondary pharmacology modulation and therefore facilitate the overall pre-clinical safety translation assessment. Following an extensive literature review, we built two separate models recapitulating known regulation processes in dogs and rats. We describe the resulting models and show that they can reproduce a variety of interventions in both species. We also show that the models can incorporate the mechanisms of action of a pre-defined list of 50 pharmacological mechanisms whose modulation predict results consistent with known pharmacology. In conclusion, a mechanistic model of hemodynamics regulations in rat and dog species has been developed to support mechanism-based safety translation in drug discovery and development.
制药公司通常会对化合物进行血流动力学相关安全风险筛查。二级药理学最初用于对化合物进行优先级排序,而后续研究则用于量化风险并将其转化至人体。该策略已显示出局限性,但可通过将分子研究结果纳入基于动物的毒理学风险评估来加以改进。本研究的目的是为大鼠和犬类物种开发一个数学模型,该模型能够整合二级药理学调节作用,从而促进临床前安全性转化评估。在进行广泛的文献综述之后,我们构建了两个独立的模型,概括犬类和大鼠中已知的调节过程。我们描述了所得模型,并表明它们能够重现两个物种中的多种干预情况。我们还表明,这些模型能够纳入50种药理学机制的预定义列表的作用机制,其调节作用预测的结果与已知药理学一致。总之,已开发出大鼠和犬类物种血流动力学调节的机制模型,以支持药物发现和开发中基于机制的安全性转化。